In the same year, another report with a modest sample size found higher levels of GFAP and NfL in the plasma of COVID-19 patients with encephalopathy compared to neuro-COVID-19 patients, defined as those with neurological manifestations associated with COVID-19, including cognitive, sensory, and motor deficits, who never required hospitalization. This evidence concerns the gene GFAP and COVID-19.